NCT03997123: Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 3
Drug Category: Serine-Threonine Kinase Inhibitor, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 130 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior treatment of AKT, PI3K, and/or mTOR inhibitors
https://ClinicalTrials.gov/show/NCT03997123

Comments are closed.

Up ↑